High Out-of-Pocket Costs Drive GLP-1 Discontinuation, Study Finds
Out-of-pocket costs drive patients to stop glucagon-like peptide-1 receptor agonists just as frequently as adverse gastrointestinal side effects like vomiting, according to survey data presented at Obesity Week 2026. While … Read More